Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Sotagliflozin Formulations
NCT03776227Phase 1Completed
- Sponsor
- Sanofi
- Start
- Jan 2019
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sotagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sanofi. Primary endpoints: Maximum Plasma Concentration at Day 1 and Area Under the Curve 0-72h. Started Jan 2019; status: completed.
02
Drugs
sotagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03776227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03776227.